Kairos Pharma, LTD. — Director's Dealing 2025

Nov 26, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2025-10-08

Reporting Person: Yu John S (Director, CEO and Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-08	COMMON STOCK	A	190840	$0.00	Acquired	230105	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
COMMON STOCK	5316572	Indirect

Footnotes

F1: Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date.

F2: Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting.